Heart shield for chemo: carvedilol may guard against toxicity
NCT ID NCT04023110
First seen Nov 01, 2025 · Last updated May 22, 2026 · Updated 31 times
Summary
This early-phase study tested whether the heart medication carvedilol could safely prevent heart damage in breast cancer patients receiving chemotherapy with doxorubicin and/or trastuzumab. Researchers assigned 68 women to either usual care or carvedilol based on their risk of heart problems. The main goals were to see if the approach was safe, tolerable, and feasible, not to prove it works. Results focused on heart function and medication adherence.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEART FAILURE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Abramson Cancer Center of the University of Pennsylvania
Philadelphia, Pennsylvania, 19104, United States
Conditions
Explore the condition pages connected to this study.